Latest News

  • INSIGHTS

    2 Feb 2026

    A $20M Bet That Brain Implants Can Fix Drug Failure
  • RESEARCH

    30 Jan 2026

    A Flash of Light, No Injection Required
  • REGULATORY

    29 Jan 2026

    Can FDA’s Softer Rules Spark a Cell Therapy Boom?
  • PARTNERSHIPS

    27 Jan 2026

    How a New Partnership Is Changing Complex Drug Design

A $55 Price Tag and a Big Test for US Insulin

Person administering insulin using a pen injector at home

INNOVATION

23 Jan 2026

Civica Rx’s planned 2026 insulin launch tests new pricing signals, insurance dynamics, and the public sector’s role in drug delivery

Cl ose-up of a tiny implant device inspected during drug delivery research

INSIGHTS

2 Feb 2026

A $20M Bet That Brain Implants Can Fix Drug Failure

CraniUS Therapeutics’ $20M raise highlights implant-based delivery as a potential solution to the brain access challenge shaping neurology...

Light activated microneedle drug delivery patch shown in laboratory research

RESEARCH

30 Jan 2026

A Flash of Light, No Injection Required

Early pre-clinical studies suggest light-triggered microneedle patches could one day reduce reliance on injections, pending further valida...

US Food and Drug Administration logo on exterior signage

REGULATORY

29 Jan 2026

Can FDA’s Softer Rules Spark a Cell Therapy Boom?

New FDA flexibility on manufacturing may ease deal friction and shape future M&A in cell and gene therapy

Pharmaceutical technicians working in a cleanroom drug development laboratory

PARTNERSHIPS

27 Jan 2026

How a New Partnership Is Changing Complex Drug Design

MedTech Pharma and BioInnovations USA unite to integrate drug delivery earlier in complex therapy development

Person administering insulin using a pen injector at home

INNOVATION

23 Jan 2026

A $55 Price Tag and a Big Test for US Insulin

Civica Rx’s planned 2026 insulin launch tests new pricing signals, insurance dynamics, and the public sector’s role in drug delivery

Exterior of a Catalent pharmaceutical manufacturing facility

TECHNOLOGY

21 Jan 2026

The Hidden Shift Behind Novo’s Catalent Acquisition

Novo’s Catalent buyout spotlights a shift toward digital quality systems built to speed drug production without sacrificing compliance

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.